Abstract:Endocan is an endothelial-cell-specific proteoglycan (ESM-1) and has emerged as an endothelial dysfunction and inflammatory marker in recent years. Endocan can be used as a marker of inflammatory endothelial dysfunction in endothelium-dependent disease: cardiovascular disease, sepsis, lung and kidney disease and malignancies. Recent data suggest that endothelial dysfunction is a key mechanism in COVID-19 pathogenesis. Endotheliitis and thrombo-inflammation are associated with severe forms of SARS-CoV-2 infection, and endocan is currently under investigation as a potential diagnostic and prognostic marker. The aim of this study was to determine serum endocan levels in patients with COVID-19 to evaluate the correlation between endocan levels and clinical disease diagnosis and prognosis. This study enrolled 56 patients, divided into three groups depending on disease severity: mild (15), moderate (25) and severe (16). The biochemical, demographic, clinical and imagistic data were collected and evaluated in correlation with the endocan levels. Serum endocan levels were significantly higher in the COVID-19 patients compared to the control group; also, endocan concentration correlated with vaccination status. The results revealed significantly elevated serum endocan levels in COVID-19 patients compared to the control group, with a correlation observed between endocan concentration and vaccination status. These findings suggest that endocan may serve as a novel biomarker for detecting inflammation and endothelial dysfunction risk in COVID-19 patients. There was no significant relationship between serum endocan levels and disease severity or the presence of cardiovascular diseases. Endocan can be considered a novel biomarker for the detection of inflammation and endothelial dysfunction risk in COVID-19 patients.

What problem does this paper attempt to address?

The paper attempts to address the issue of evaluating changes in serum Endocan levels in COVID-19 patients and exploring its relationship with disease diagnosis, prognosis, and patients' biochemical characteristics and vaccination status. Specifically, the study aims to determine whether serum Endocan levels can serve as a new biomarker for detecting the risk of inflammation and endothelial dysfunction in COVID-19 patients. ### Research Background - **Endocan**: Endocan is a specific endothelial cell proteoglycan (ESM-1) that has been used in recent years as a marker of endothelial dysfunction and inflammation. - **Pathological Mechanism of COVID-19**: Studies have shown that endothelial dysfunction is one of the key mechanisms in the pathogenesis of COVID-19. Endothelialitis and thromboinflammation are associated with severe forms of SARS-CoV-2 infection, making Endocan a potential diagnostic and prognostic marker. ### Research Methods - **Study Subjects**: The study included 56 COVID-19 patients, divided into three groups based on disease severity: mild (15 patients), moderate (25 patients), and severe (16 patients). - **Data Collection**: Biochemical, demographic, clinical, and imaging data were collected from the patients and correlated with Endocan levels. ### Main Findings - **Endocan Levels**: Serum Endocan levels were significantly elevated in COVID-19 patients compared to the control group. - **Vaccination Status**: Endocan concentrations were related to vaccination status, with higher levels observed in unvaccinated patients. - **Inflammation and Endothelial Dysfunction**: Endocan levels were positively correlated with inflammatory markers (such as CRP, IL6) and coagulation markers (such as D-dimer). - **Disease Severity**: Although Endocan levels varied among patients with different severity levels, the differences were not statistically significant. ### Conclusion - **Endocan as a Biomarker**: The study results suggest that Endocan may serve as a new biomarker for detecting the risk of inflammation and endothelial dysfunction in COVID-19 patients. - **Future Research Directions**: Further research is needed to validate the diagnostic and prognostic value of Endocan in COVID-19 patients, especially in combination with other inflammatory and coagulation markers. Through these findings, the researchers hope to provide new biological evidence for the management and treatment of COVID-19 patients.

Investigation of Serum Endocan Levels in SARS-CoV-2 Patients

Endothelial cell-specific molecule-1/endocan: Diagnostic and prognostic value in patients suffering from severe sepsis and septic shock

Endocan as a biomarker for acute respiratory distress syndrome: A systematic review and meta-analysis

Endocan is useful biomarker of survival and severity in sepsis

Endocan: A Key Player of Cardiovascular Disease

Relationship Between Endothelial and Angiogenesis Biomarkers Envisage Mortality in a Prospective Cohort of COVID-19 Patients Requiring Respiratory Support

Comparison of Different Vascular Biomarkers for Predicting In-Hospital Mortality in Severe SARS-CoV-2 Infection

Serum VEGF-A levels on admission in COVID-19 patients correlate with SP-D and neutrophils, reflecting disease severity: A prospective study

Circulating endocannabinoid levels in SARS-CoV-2 infection and their potential role in the inflammatory response

Endothelial biomarkers (Von willebrand factor, BDCA3, urokinase) as predictors of mortality in COVID-19 patients: cohort study

Serum Levels of Intercellular Adhesion Molecule-1 and TNF- in Patients with COVID-19 and Its Relation to Disease Severity

Endothelial dysfunction and cardiovascular risk in post-COVID-19 patients after 6- and 12-months SARS-CoV-2 infection

Endocan may predict the presence of coronary slow flow and coronary artery disease

Elevated Expression of Serum Endothelial Cell Adhesion Molecules in COVID-19 Patients

Comparison of C-reactive protein with distinct hyperinflammatory biomarkers in association with COVID-19 severity, mortality and SARS-CoV-2 variants

Endothelial glycocalyx damage in patients with severe COVID-19 on mechanical ventilation - A prospective observational pilot study

An observational study investigating soluble immune checkpoints as indicators of severe COVID-19

Ceramides As Potential New Predictors of the Severity of Acute Coronary Syndrome in Conjunction with SARS-CoV-2 Infection

Host Response Markers of Inflammation and Endothelial Activation Associated with COVID-19 Severity and Mortality: A GeoSentinel Prospective Observational Cohort

Diagnostic Role of Circulating Endocan Levels in Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis

Novel prognostic impact and cell specific role of endocan in patients with coronary artery disease